Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News Macro

Medicare Shakeup: Policy Changes Rattle Big Insurers

by Team Lumida
May 17, 2024
in Macro, News
Reading Time: 4 mins read
A A
0
emergency signage

Photo by Pixabay on Pexels.com

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways

  1. Biden administration’s policy changes reduce Medicare Advantage profitability.
  2. Insurers like CVS and Humana face rising costs and declining profits.
  3. Market and regulatory challenges could reshape the future of Medicare Advantage.

What Happened?

The Medicare Advantage landscape has dramatically shifted. Medicare Advantage, a program where the government pays insurers to manage senior care, has been a major profit driver for companies like UnitedHealth Group and Humana. However, the Biden administration’s recent policy changes have altered the payment structures, causing a significant dip in profitability.

CVS Health’s Aetna unit reported a $900 million surge in unexpected medical costs, leading to its largest one-day share drop in nearly 15 years. As a result, CVS shares have plunged 26% this year, equating to a market cap of just over $70 billion—the same amount it paid for Aetna in 2018. Humana and UnitedHealth have also seen their shares drop by over 20% and 16%, respectively.

Why It Matters?

These changes have rattled investors and corporate boards, signaling a shift from growth to profitability in the Medicare Advantage sector. With the government tightening its purse strings and implementing stricter policies, insurers must adapt quickly. CVS plans to exit some markets and cut back on benefits to improve margins.

Thomas Cowhey, CVS Chief Financial Officer, stated, “The goal for next year is margin over membership.” This shift could open opportunities for companies with better profit margins like UnitedHealth to gain market share. However, the regulatory environment remains a tougher challenge, with tighter payment rates and changes in coding patient risk.

What’s Next?

Insurers are now focusing on mitigating rising costs and adapting to new regulations. Expect strategic exits from less profitable markets and reductions in member benefits. Analysts predict Humana, despite expected lower earnings this year, will rebound to $26 per share by 2026. The industry’s lobbying efforts will intensify to influence public and policymaker opinions.

Wendell Potter, a former Cigna executive, highlighted, “Companies will be investing heavily through campaign donations and lobbying.” A potential Donald Trump win in the upcoming presidential elections could favor privatization and benefit Medicare Advantage. Regardless, the sector remains profitable but without the extraordinary gains seen in recent years.

Source: WSJ
Previous Post

Why Bitcoin’s Correlation with Nasdaq Is Skyrocketing

Next Post

Pharmacy Facelift: How Walgreens and CVS Aim to Boost Profits

Recommended For You

KKR Lifts Its 10-Year Treasury Call to 5.1% and Pushes the Fed Hold Out to Early 2029

by Team Lumida
12 hours ago
KKR Lifts Its 10-Year Treasury Call to 5.1% and Pushes the Fed Hold Out to Early 2029

KKR now expects hikes in December and March, then rates held at that level for nearly three years, citing Warsh concern over persistent inflation.

Read more

JPMorgan Puts Oil Fair Value at $90 Against a $106 Price, Implying 4 Million Barrels a Day of Additional Loss Risk

by Team Lumida
12 hours ago
Dollar Steadies, Euro and Sterling Vulnerable as Markets Await Fed Decision; Bitcoin Trades at 4-Week Lows

Six months into the Iran war, JPMorgan says every economic red line it assumed Washington would not cross has been crossed, leaving no model for how it ends.

Read more

Three New ETFs Target Tax Deferral, Next-Generation AI Winners and Hedged Bitcoin Exposure

by Team Lumida
13 hours ago
Three New ETFs Target Tax Deferral, Next-Generation AI Winners and Hedged Bitcoin Exposure

Bloomberg Trillions reviews three recent ETF launches covering tax-deferred structures, an AI index beyond the megacaps, and a hedged bitcoin product.

Read more

Chip Gauge Jumps 3% and 10-Year Yields Snap an Eight-Day Rising Streak as Brent Slides to $104

by Team Lumida
13 hours ago
S&P 500’s Big Earnings Test: Will Tech Slowdown Derail Gains?

Stocks and bonds rallied the day after the Fed first hike since 2023, driven by falling oil rather than anything the central bank said.

Read more

Shorts Take $208 Million of a $345 Million Liquidation Wave as Bitcoin Holds $76,000 Through the Fed Hike

by Team Lumida
19 hours ago
SEC Approval Boosts Crypto Funds: $1.2B Invested in a Week

Bitcoin barely moved on the Fed first hike of the cycle while 86,816 traders were liquidated, with bears absorbing most of the damage and Zcash running 17%.

Read more

US Stock Futures Rally Post-Fed as Oil Falls, Treasury Yields Decline; Nasdaq 100 Futures Up 1.1%, Tech Leads Rebound

by Team Lumida
20 hours ago
US Stock Futures Rally Post-Fed as Oil Falls, Treasury Yields Decline; Nasdaq 100 Futures Up 1.1%, Tech Leads Rebound

S&P 500 futures +0.8%, Nasdaq 100 futures +1.1% as Brent crude falls 2.2%; semiconductors surge on lower yields supporting AI demand.

Read more

Novo Nordisk Partners With Orbis for Oral Biologic Pills Worth $1.4B; Eli Lilly Also Stakeholder in AI Drug Design Startup

by Team Lumida
20 hours ago
Novo Nordisk Partners With Orbis for Oral Biologic Pills Worth $1.4B; Eli Lilly Also Stakeholder in AI Drug Design Startup

Novo invests in Orbis to develop oral versions of Ozempic/Wegovy; Orbis uses AI for compound design; Eli Lilly competing as stakeholder.

Read more

How to Bet on Oil Without Owning a Barrel: Retail Traders Navigate Crude Products From ETFs to Perpetual Futures

by Team Lumida
20 hours ago
How to Bet on Oil Without Owning a Barrel: Retail Traders Navigate Crude Products From ETFs to Perpetual Futures

Energy ETFs (XLE, VDE) safest; futures-linked (USO, BNO) track crude but face contango drag; dynamic roll funds (DBO, USL) mitigate; crypto/blockchain/perps carry high risk.

Read more

Treasuries Surge on Warsh Credibility; 10-Year Yields Fall to 4.98% After Fed Rate Hike Signals Inflation Fight Commitment

by Team Lumida
20 hours ago
BlackRock’s Larry Fink on Economic Growth and Market Misconceptions

Bond market rallies on confidence in Fed Chair; 10-year yields fall 4bps from 5% peak; BOJ, BOE meetings Thursday could extend global rate-hike cycle.

Read more

China’s US Treasury Holdings Hit 18-Year Low at $618B; Geopolitical Rift and Yield Spike Fears Drive Diversification to Gold, Agency Bonds

by Team Lumida
22 hours ago
China’s US Treasury Holdings Hit 18-Year Low at $618B; Geopolitical Rift and Yield Spike Fears Drive Diversification to Gold, Agency Bonds

China reduces Treasury holdings to lowest since Aug 2008 from $1.3T peak; diversifies into gold, agency bonds, equities as US debt surpasses $40T.

Read more
Next Post
woman with face mask holding an alcohol bottle

Pharmacy Facelift: How Walgreens and CVS Aim to Boost Profits

Revolutionizing AI: How DePIN is Solving Robots’ Biggest Blind Spot

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

a golden bitcoin sitting on top of a black table

Nasdaq to Launch Bitcoin Options: What It Means for Investors

August 27, 2024
China’s AI Startups Challenge Global Leaders Amid U.S. Trade Curbs

Wall Street’s Hottest Trade Has Gone Ice Cold — The AI Momentum Unwind Arrives

August 31, 2026
AI Search Startup Perplexity Hits $14 Billion Valuation in $500 Million Funding Round

AI Search Startup Perplexity Hits $14 Billion Valuation in $500 Million Funding Round

May 13, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018